{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:59:44Z","timestamp":1787165984481,"version":"build-2736575974"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2017,4,19]],"date-time":"2017-04-19T00:00:00Z","timestamp":1492560000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,3,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Although cardiovascular disease is a major health burden for patients with chronic kidney disease, most cardiovascular outcome trials have excluded patients with advanced chronic kidney disease. Moreover, the major cardiovascular outcome trials that have been conducted in patients with end-stage renal disease have not demonstrated a treatment benefit. Thus, clinicians have limited evidence to guide the management of cardiovascular disease in patients with chronic kidney disease, particularly those on dialysis. Several factors contribute to both the paucity of trials and the apparent lack of observed treatment effect in completed studies. Challenges associated with conducting trials in this population include patient heterogeneity, complexity of renal pathophysiology and its interaction with cardiovascular disease, and competing risks for death. The Investigator Network Initiative Cardiovascular and Renal Clinical Trialists (INI-CRCT), an international organization of academic cardiovascular and renal clinical trialists, held a meeting of regulators and experts in nephrology, cardiology, and clinical trial methodology. The group identified several research priorities, summarized in this paper, that should be pursued to advance the field towards achieving improved cardiovascular outcomes for these patients. Cardiovascular and renal clinical trialists must partner to address the uncertainties in the field through collaborative research and design clinical trials that reflect the specific needs of the chronic and end-stage kidney disease populations, with the shared goal of generating robust evidence to guide the management of cardiovascular disease in patients with kidney disease.<\/jats:p>","DOI":"10.1093\/eurheartj\/ehx209","type":"journal-article","created":{"date-parts":[[2017,3,31]],"date-time":"2017-03-31T03:57:33Z","timestamp":1490932653000},"page":"880-886","source":"Crossref","is-referenced-by-count":45,"title":["Cardiovascular outcome trials in patients with chronic kidney disease: challenges associated with selection of patients and endpoints"],"prefix":"10.1093","volume":"40","author":[{"given":"Patrick","family":"Rossignol","sequence":"first","affiliation":[{"name":"Inserm, Centre d\u2019Investigations Cliniques- 1433, and Inserm U1116; CHRU Nancy; Universit\u00e9 de Lorraine; Association Lorraine pour le Traitement de l\u2019Insuffisance R\u00e9nale, Institut lorrain du C\u0153ur et des Vaisseaux Louis Mathieu, 4 rue du Morvan, Nancy, France"},{"name":"F-CRIN INI-CRCT, Nancy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajiv","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA"},{"name":"Richard L. Roudebush Veterans Administration Medical Center, Indianapolis, IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Canaud","sequence":"additional","affiliation":[{"name":"Fresenius Medical Care Deutschland and University of Montpellier, UFR Medicine, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Charney","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Chatellier","sequence":"additional","affiliation":[{"name":"AP-HP, H\u00f4pital Europ\u00e9en Georges Pompidou, Unit\u00e9 de Recherche Clinique and INSERM CIC 1418, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan C","family":"Craig","sequence":"additional","affiliation":[{"name":"School of Public Health, The University of Sydney, New South Wales, Australia"},{"name":"Centre for Kidney Research, The Children's Hospital at Westmead, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C","family":"Cushman","sequence":"additional","affiliation":[{"name":"Preventive Medicine Section, Veterans Affairs Medical Center, Memphis, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald T","family":"Gansevoort","sequence":"additional","affiliation":[{"name":"Department of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bengt","family":"Fellstr\u00f6m","sequence":"additional","affiliation":[{"name":"Inserm U1018, Universit\u00e9 Paris-Saclay, UVSQ, Universit\u00e9. Paris-Sud, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dahlia","family":"Garza","sequence":"additional","affiliation":[{"name":"Relypsa, Inc., Redwood City, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Guzman","sequence":"additional","affiliation":[{"name":"AstraZeneca, Gaithersburg, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank A","family":"Holtkamp","sequence":"additional","affiliation":[{"name":"Dutch Medicines Evaluation Board, Utrecht, The Netherlands"},{"name":"Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard M","family":"London","sequence":"additional","affiliation":[{"name":"F-CRIN INI-CRCT, Nancy, France"},{"name":"France Centre Hospitalier F.H. Manh\u00e8s, Fleury-Merogis, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziad A","family":"Massy","sequence":"additional","affiliation":[{"name":"F-CRIN INI-CRCT, Nancy, France"},{"name":"Ambroise Pare University Hospital, APHP, Paris-Ile-de France-Ouest University (UVSQ), and INSERM U1018, Team 5 Boulogne Billancourt, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Mebazaa","sequence":"additional","affiliation":[{"name":"F-CRIN INI-CRCT, Nancy, France"},{"name":"U942 Inserm, Paris, France"},{"name":"University Paris Diderot, Sorbonne Paris Cit\u00e9, Paris, France"},{"name":"APHP, Department of Anesthesia and Critical Care, H\u00f4pitaux Universitaires Saint Louis-Lariboisi\u00e8re, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter G M","family":"Mol","sequence":"additional","affiliation":[{"name":"Dutch Medicines Evaluation Board, Utrecht, The Netherlands"},{"name":"Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc A","family":"Pfeffer","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Rosenberg","sequence":"additional","affiliation":[{"name":"National Heart, Lung, and Blood Institute, Bethesda, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis M","family":"Ruilope","sequence":"additional","affiliation":[{"name":"Institute of Investigation and Hypertension Unit, Hospital 12 de Octubre, Department of Preventive Medicine and Public Health, Universidad Autonoma and School of Doctoral Studies and Research, Universidad Europea de Madrid, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Seltzer","sequence":"additional","affiliation":[{"name":"ACI Clinical, Bala Cynwyd, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amil M","family":"Shah","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salim","family":"Shah","sequence":"additional","affiliation":[{"name":"Sarfez Pharmaceuticals, Inc., McLean, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhupinder","family":"Singh","sequence":"additional","affiliation":[{"name":"ZS Pharma, San Mateo, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bergur V","family":"Stef\u00e1nsson","sequence":"additional","affiliation":[{"name":"AstraZeneca, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman","family":"Stockbridge","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular and Renal Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy Gattis","family":"Stough","sequence":"additional","affiliation":[{"name":"Campbell University College of Pharmacy and Health Sciences, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian","family":"Thygesen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Walsh","sequence":"additional","affiliation":[{"name":"McMaster University and Population Health Research Institute, Hamilton, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Wanner","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine 1, University Hospital W\u00fcrzburg and Comprehensive Heart Failure Center, W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G","family":"Warnock","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher S","family":"Wilcox","sequence":"additional","affiliation":[{"name":"Hypertension, Kidney and Vascular Research Center and Division of Nephrology and Hypertension, Department of Medicine, Georgetown University, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Wittes","sequence":"additional","affiliation":[{"name":"Statistics Collaborative, Inc., Washington, District of Columbia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertram","family":"Pitt","sequence":"additional","affiliation":[{"name":"University of Michigan School of Medicine, Ann Arbor, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliza","family":"Thompson","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular and Renal Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[{"name":"Inserm, Centre d\u2019Investigations Cliniques- 1433, and Inserm U1116; CHRU Nancy; Universit\u00e9 de Lorraine; Association Lorraine pour le Traitement de l\u2019Insuffisance R\u00e9nale, Institut lorrain du C\u0153ur et des Vaisseaux Louis Mathieu, 4 rue du Morvan, Nancy, France"},{"name":"F-CRIN INI-CRCT, Nancy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,4,18]]},"reference":[{"key":"2019072505400647700_ehx209-B1","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1161\/CIRCULATIONAHA.115.018713","article-title":"Epidemiology and mechanisms of uremia-related cardiovascular disease","volume":"133","author":"Tonelli","year":"2016","journal-title":"Circulation"},{"key":"2019072505400647700_ehx209-B2","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A randomized trial of intensive versus standard blood-pressure control","volume":"373","author":"Wright","year":"2015","journal-title":"N Engl J Med"},{"key":"2019072505400647700_ehx209-B3","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1001\/jama.296.11.1377","article-title":"Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease","volume":"296","author":"Coca","year":"2006","journal-title":"Jama"},{"key":"2019072505400647700_ehx209-B4","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1001\/jamainternmed.2015.6102","article-title":"Representation of patients with kidney disease in trials of cardiovascular interventions: an updated systematic review","volume":"176","author":"Konstantinidis","year":"2016","journal-title":"JAMA Intern Med"},{"key":"2019072505400647700_ehx209-B5","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0140-6736(13)60595-4","article-title":"Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention","volume":"382","author":"Gansevoort","year":"2013","journal-title":"Lancet"},{"key":"2019072505400647700_ehx209-B6","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1038\/nrcardio.2014.97","article-title":"Does cardiovascular protection translate into renal protection?","volume":"11","author":"Ruiz-Hurtado","year":"2014","journal-title":"Nat Rev Cardiol"},{"key":"2019072505400647700_ehx209-B7","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nrcardio.2016.48","article-title":"Global cardiovascular protection in chronic kidney disease","volume":"13","author":"Ruiz-Hurtado","year":"2016","journal-title":"Nat Rev Cardiol"},{"key":"2019072505400647700_ehx209-B8","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1001\/jamainternmed.2015.6403","article-title":"Exclusion of patients with kidney disease from cardiovascular trials","volume":"176","author":"Ishida","year":"2016","journal-title":"JAMA Intern Med"},{"key":"2019072505400647700_ehx209-B9","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1365-2796.2009.02204.x","article-title":"Relation between renal function, presentation, use of therapies and in-hospital complications in acute coronary syndrome: data from the SWEDEHEART register","volume":"268","author":"Szummer","year":"2010","journal-title":"J Intern Med"},{"key":"2019072505400647700_ehx209-B10","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1016\/S0140-6736(14)60384-6","article-title":"Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure","volume":"383","author":"Ortiz","year":"2014","journal-title":"Lancet"},{"key":"2019072505400647700_ehx209-B11","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"key":"2019072505400647700_ehx209-B12","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa1205624","article-title":"Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis","volume":"367","author":"Chertow","year":"2012","journal-title":"N Engl J Med"},{"key":"2019072505400647700_ehx209-B13","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1093\/eurheartj\/eht013","article-title":"Antithrombotic outcome trials in acute coronary syndromes: seeking the optimal balance between safety and efficacy","volume":"34","author":"Verheugt","year":"2013","journal-title":"Eur Heart J"},{"key":"2019072505400647700_ehx209-B14","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1093\/eurjhf\/hft095","article-title":"Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document","volume":"15","author":"Zannad","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"2019072505400647700_ehx209-B15","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1681\/ASN.2014010108","article-title":"High-sensitivity troponin T and N-terminal pro-B-type natriuretic peptide (NT-proBNP) and risk of incident heart failure in patients with CKD: the Chronic Renal Insufficiency Cohort (CRIC) Study","volume":"26","author":"Bansal","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"2019072505400647700_ehx209-B16","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.jacc.2014.01.020","article-title":"Proposal for a functional classification system of heart failure in patients with end-stage renal disease: proceedings of the acute dialysis quality initiative (ADQI) XI workgroup","volume":"63","author":"Chawla","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2019072505400647700_ehx209-B17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.echo.2014.10.003","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"28","author":"Lang","year":"2015","journal-title":"J Am Soc Echocardiogr"},{"key":"2019072505400647700_ehx209-B18","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1373\/clinchem.2015.251835","article-title":"Prognostic value of serial changes in high-sensitivity cardiac troponin I and T over 3\u2009months using reference change values in hemodialysis patients","volume":"62","author":"Sandoval","year":"2016","journal-title":"Clin Chem"},{"key":"2019072505400647700_ehx209-B19","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jacc.2014.12.018","article-title":"2014 ACC\/AHA key data elements and definitions for cardiovascular endpoint events in clinical trials: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards)","volume":"66","author":"Hicks","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2019072505400647700_ehx209-B20","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0140-6736(16)31331-9","article-title":"A roadmap to design future cardiovascular prevention trials in chronic kidney disease","volume":"388","author":"Rossignol","year":"2016","journal-title":"Lancet"},{"key":"2019072505400647700_ehx209-B21","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1093\/ndt\/gfi145","article-title":"Dynamic changes in right ventricular pressures during haemodialysis recorded with an implantable haemodynamic monitor","volume":"21","author":"Braunschweig","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"2019072505400647700_ehx209-B22","first-page":"119","article-title":"Changes in right ventricular pressures between hemodialysis sessions recorded by an implantable hemodynamic monitor","volume":"103","author":"Kjellstrom","year":"2009","journal-title":"Am J Cardiol"},{"key":"2019072505400647700_ehx209-B23","doi-asserted-by":"crossref","first-page":"502","DOI":"10.7326\/M14-0746","article-title":"Role of troponin in patients with chronic kidney disease and suspected acute coronary syndrome","volume":"161","author":"Stacy","year":"2014","journal-title":"systematic review. Ann Intern Med"},{"key":"2019072505400647700_ehx209-B24","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1093\/eurheartj\/ehs184","article-title":"Third universal definition of myocardial infarction","volume":"33","author":"Thygesen","year":"2012","journal-title":"Eur Heart J"},{"key":"2019072505400647700_ehx209-B25","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1016\/j.jacc.2015.10.036","article-title":"Design of major randomized trials: part 3 of a 4-part series on statistics for clinical trials","volume":"66","author":"Pocock","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2019072505400647700_ehx209-B26","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1093\/eurheartj\/ehu205","article-title":"The importance of patient-reported outcomes: a call for their comprehensive integration in cardiovascular clinical trials","volume":"35","author":"Anker","year":"2014","journal-title":"Eur Heart J"},{"key":"2019072505400647700_ehx209-B27","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1002\/ejhf.516","article-title":"Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency","volume":"18","author":"Anker","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2019072505400647700_ehx209-B28","year":"1 2016"},{"key":"2019072505400647700_ehx209-B29","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/ije\/dyu222","article-title":"Modelling recurrent events: a tutorial for analysis in epidemiology","volume":"44","author":"Amorim","year":"2015","journal-title":"Int J Epidemiol"},{"key":"2019072505400647700_ehx209-B30","doi-asserted-by":"crossref","first-page":"e34785.","DOI":"10.1371\/journal.pone.0034785","article-title":"Designing and analyzing clinical trials with composite outcomes: consideration of possible treatment differences between the individual outcomes","volume":"7","author":"Pogue","year":"2012","journal-title":"PLoS One"},{"key":"2019072505400647700_ehx209-B31","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ahj.2014.10.002","article-title":"Incorporating patient preferences into clinical trial design: results of the opinions of patients on treatment implications of new studies (OPTIONS) project","volume":"169","author":"Stafinski","year":"2015","journal-title":"Am Heart J"},{"key":"2019072505400647700_ehx209-B32","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1016\/S0140-6736(16)31894-3","article-title":"Improving outcomes of dialysis patients by population health management-the Global Chief Medical Officer Initiative","volume":"388","author":"Canaud","year":"2016","journal-title":"Lancet"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/eurheartj\/article-pdf\/40\/11\/880\/28998289\/ehx209.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:49:57Z","timestamp":1719125397000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/40\/11\/880\/3739981"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,18]]},"references-count":32,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2017,4,18]]},"published-print":{"date-parts":[[2019,3,14]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehx209","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,3,14]]},"published":{"date-parts":[[2017,4,18]]}}}